Cizzle Biotechnology Holdings PLC - Asset Resilience Ratio
Cizzle Biotechnology Holdings PLC (CIZ) has an Asset Resilience Ratio of 83.46% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CIZ net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2023)
This chart shows how Cizzle Biotechnology Holdings PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cizzle Biotechnology Holdings PLC balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Cizzle Biotechnology Holdings PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CIZ current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.41 Million | 83.46% |
| Total Liquid Assets | GBX1.41 Million | 83.46% |
Asset Resilience Insights
- Very High Liquidity: Cizzle Biotechnology Holdings PLC maintains exceptional liquid asset reserves at 83.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cizzle Biotechnology Holdings PLC Industry Peers by Asset Resilience Ratio
Compare Cizzle Biotechnology Holdings PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Cizzle Biotechnology Holdings PLC (2023–2023)
The table below shows the annual Asset Resilience Ratio data for Cizzle Biotechnology Holdings PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 83.46% | GBX1.41 Million ≈ $171.92 |
GBX1.69 Million ≈ $205.99 |
-- |
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more